title: Antihyperlipidemic therapies targeting PCSK9: Novel therapeutic agents for lowering low-density lipoprotein cholesterol.
authors.affiliation: Department of Clinical Laboratory, Affiliated Nanhua Hospital, University of South China, No. 336 Dongfeng South Road, Hengyang 421001, Hunan, China. Electronic address: mihualiu@163.com.
authors.forename: Mi-Hua
authors.initials: MH
authors.lastname: Liu
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D050197:Atherosclerosis / Q000378:metabolism / Q000517:prevention & control; D008078:Cholesterol, LDL / Q000378:metabolism*; D002986:Clinical Trials as Topic; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology; D058990:Molecular Targeted Therapy / Q000379:methods; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors / Q000378:metabolism; D012697:Serine Endopeptidases / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; C000600650:RG7652; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases; C577155:evolocumab
keywords: LDL-C; Lipid metabolism; PCSK9; Statins